Acute Kidney Injury Therapeutics Market Size in the 7MM was ~USD 6200 Million in 2022, estimated DelveInsight

DelveInsight's "Acute Kidney Injury Market Insights, Epidemiology and Market Forecast-2034" report delivers an in-depth understanding of the Acute Kidney Injury, historical and forecasted epidemiology as well as the Acute Kidney Injury market trends in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.

Discover Key Insights into the Acute Kidney Injury Market with DelveInsight's In-Depth Report @ Acute Kidney Injury Market Size [https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Acute Kidney Injury Market Report

* In November 2024:- CSL Behring- This study consists of two parts: phase 2 (Part A) and phase 3 (Part B). It is a multicenter study designed to evaluate the safety, effectiveness, and pharmacokinetics (PK) of CSL889 (human hemopexin) when given intravenously (IV) to adults and adolescents with sickle cell disease (SCD) experiencing vaso-occlusive crises (VOC). The main objectives of the study are to assess how CSL889 affects the time it takes for VOC to resolve in participants with SCD, and to evaluate the safety and tolerability of CSL889 in study participants.
* In November 2024:- Alexion Pharmaceuticals, Inc.- The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac surgery with CPB.
* The total Mortality-adjusted Incident Cases of Acute Kidney Injury in the 7MM comprised 14.6 million cases in 2022 and are projected to increase during the forecast period.
* The total Mortality-adjusted Incident Cases of Acute Kidney Injury in the United States were approximately 5.7 in 2022.
* The US contributed to the largest incident population of Acute Kidney Injury, accounting for ~ 39% in the 7MM in 2022.
* Among EU4 and the UK, Germany accounted for the highest number of Acute Kidney Injury cases, followed by France, whereas Spain accounted for the lowest cases in 2022.
* The stage-specific cases of Acute Kidney Injury include Stage I, Stage II, and, Stage III. Out of which maximum cases were reported in stage I Acute Kidney Injury followed by stage II and Stage III.
* The leading Acute Kidney Injury Companies such as Alexion Pharmaceuticals, Alloksys Life Sciences, Am-pharma, Aptabio Therapeutics, Arch Biopartners, Guard Therapeutics, Novartis Pharmaceuticals, Ocelot Bio, Rediscovery Life Sciences, Renibus Therapeutics, River 2 Renal , and others.
* Promising Acute Kidney Injury Pipeline Therapies such as TIN816, SCD-F40, THR-184, ABT-719, QPI-1002, ASP1128, LSALT Peptide , and others.

Stay ahead in the Acute Kidney Injury Therapeutics Market with DelveInsight's Strategic Report @ Acute Kidney Injury Market Outlook [https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Acute Kidney Injury Epidemiology Segmentation in the 7MM

* Total Acute Kidney Injury Incident Population in Hospitalized Patients
* Acute Kidney Injury Mortality Adjusted Incident Population
* Acute Kidney Injury Stage-specific Incident Population
* Acute Kidney Injury Age-specific Incident Population

Download the report to understand which factors are driving Acute Kidney Injury epidemiology trends @ Acute Kidney Injury Prevalence [https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Acute Kidney Injury Emerging Drugs

* RBT-1: Renibus Therapeutics

RBT-1 by Renibus Therapeutics is an investigational drug that upregulates anti-inflammatory, antioxidant, and iron-scavenging pathways, activating a cytoprotective preconditioning response to reduce the risk of postoperative complications and improve patient outcomes following cardiothoracic surgery. The RBT-1-mediated pharmacologic preconditioning is thought to induce broad organ protection, thereby mitigating the risks of postoperative complications and improving both short- and long-term outcomes. In July 2023, Renibus Therapeutics announced that the US FDA granted Breakthrough Therapy Designation to RBT-1 for the reduction in risk of postoperative complications in patients undergoing cardiothoracic surgery and confirmed its alignment with the company's planned Phase III pivotal trial. In October 2023, Renibus Therapeutics announced that the first patient had been dosed in the pivotal Phase III PROTECT trial of RBT-1. Top-line results are expected in mid-2025. NDA filing is anticipated by early 2026.

* OCE-205: Ocelot Bio

Ocelot Bio's lead asset, OCE-205, is a therapeutic peptide with a differentiated mechanism of action that has the potential to improve outcomes for patients with complications of end-stage liver disease (ESLD). OCE-205's innovation emanates from its design as a mixed agonist-antagonist peptide selective for the vasopressin 1a (V1a) receptor with no vasopressin 2 (v2) receptor activity at drug concentrations well above those used in treating ESLD. In August 2022, Ocelot Bio announced that the US FDA granted ODD to OCE-205 for the treatment of hepatorenal syndrome. Ocelot Bio has completed the enrolment of patients in a Phase II clinical trial of OCE-205 in hepatorenal syndrome with acute kidney injury (HRS-Acute Kidney Injury).

Acute Kidney Injury Market Outlook

A robust pipeline with a novel mechanism of action and increasing incidence are major market drivers of the Acute Kidney Injury therapeutics market. Additionally, the Acute Kidney Injury pipeline is also expected to change the current dynamics of the market, which presently comprises biologics and molecules with new mechanisms of action. Currently, there are no targeted pharmacotherapies approved for the treatment of Acute Kidney Injury. At present, the therapeutic market size of Acute Kidney Injury is mainly dominated by the use of RRT and off-label drugs, which include various classes such as ACE inhibitors, ARBs, Diuretics, and NSAIDs. Various comorbidities like cardiovascular disease, hypertension, diabetes mellitus, pre-existing CKD, renal recovery, and others increase the risk of Acute Kidney Injury in these patients. As mentioned earlier, the current market of Acute Kidney Injury is majorly dependent on RRT and conventional therapies like NSAIDs, ACE inhibitors, ARBs, diuretics, etc.

Get In-Depth Knowledge on Acute Kidney Injury Market Trends and Forecasts with DelveInsight @ Acute Kidney Injury Treatment Market [https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Major Acute Kidney Injury Companies

The leading Acute Kidney Injury Companies such as Atox Bio, AM-Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics Alloksys, Vifor Pharma, and others.

Scope of the Acute Kidney Injury Market Research Report

* Coverage- 7MM
* Study Period- 2020-2034
* Acute Kidney Injury Companies- Alexion Pharmaceuticals, Alloksys Life Sciences, Am-pharma, Aptabio Therapeutics, Arch Biopartners, Guard Therapeutics, Novartis Pharmaceuticals, Ocelot Bio, Rediscovery Life Sciences, Renibus Therapeutics, River 2 Renal, and others.
* Acute Kidney Injury Pipeline Therapies- TIN816, SCD-F40, THR-184, ABT-719, QPI-1002, ASP1128, LSALT Peptide, and others.
* Acute Kidney Injury Market Dynamics: Acute Kidney Injury Market Drivers and Barriers
* Acute Kidney Injury Market Access and Reimbursement, Unmet Needs, KOL's Views, and Analyst's Views

Unlock Strategic Insights with DelveInsight's Comprehensive Acute Kidney Injury Market Report @ Acute Kidney Injury Market Drivers and Barriers [https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1. KEY INSIGHTS

2. REPORT INTRODUCTION

3. EXECUTIVE SUMMARY

4. KEY EVENTS

5. EPIDEMIOLOGY AND MARKET FORECAST METHODOLOGY

6. ACUTE KIDNEY INJURY MARKET OVERVIEW AT A GLANCE

7. DISEASE BACKGROUND AND OVERVIEW

8. TREATMENT AND PREVENTION

9. GUIDELINES

10. EPIDEMIOLOGY AND PATIENT POPULATION

11. PATIENT JOURNEY

12. EMERGING DRUGS

13. Acute Kidney Injury: THE 7MM ANALYSIS

14. KOL VIEWS

15. UNMET NEEDS

16. SWOT ANALYSIS

17. MARKET ACCESS AND REIMBURSEMENT

18. APPENDIX

19. DELVEINSIGHT CAPABILITIES

20. DISCLAIMER

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acute-kidney-injury-therapeutics-market-size-in-the-7mm-was-usd-6200-million-in-2022-estimated-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage



This release was published on openPR.